2012年5月20-23日· Mandalay Bay Resort & Casino · Las Vegas, NV
Therapeutic Oligonucleotide Development: A Promising Outlook
Art Krieg, M.D., Entrepreneur in Residence, Atlas Ventures
Resources to Enable and Facilitate siRNA Drug Development in China
Zicai Liang, Ph.D., Chairman, Suzhou Ribo Life Science Co., LTD, China
Harnessing the "New" Endocrinology of Peptide Hormones - Discovery of Novel Therapies Targeting Metabolic Disease
David E. Moller, M.D., Vice President, Endocrine and Cardiovascular Research and Clinical Investigation, Lilly Research Laboratories, Eli Lilly and Co.
RaPID Discovery of Natural Product-Like Peptides against Therapeutic Targets
Hiroaki Suga, Ph.D., Professor, Chemical Biology and Biotechnology Lab, The University of Tokyo, Japan
The Next Generation in Clinical Molecular Diagnostics
Trevor Hawkins, Ph.D., CEO, Next Generation Diagnostics, Siemens Healthcare Diagnostics
Update on Commercialization of RUO and IUO Products and Oversight of Lab-Developed Tests
B. Melina Cimler, Ph.D., Vice President, Quality and Regulatory, Illumina, Inc.
Special Discounted Hotel Rate Available Until April 3, 2012.
To book your room, call 702-632-9000 and reference IBC or TIDES.
TIDES 2012
(寡核苷酸以及肽的研究、技術、產品開發相關學會)
2012年5月20-23日 | Las Vegas, USA
CMC的各課題、初期製劑開發、針對藥物輸送的代替投藥技術相關案例研究
關於讓將來的計畫立案充滿活力的基礎會議
加速前臨床開發與臨床開發的藥劑般特性之改善
以治療法的開發為目的的細胞内藥、新的立足點、做為改良分子的肽之開發
透過法規、事業、技術面的最新戰略的產品開發之加速化
"I've looked over the entire agenda and the TIDES 2012 seems like it will be one of the best, if not THE best, meeting I'll attend in 2012." - Richard A. Montagna, Ph.D., Senior Vice President for Corporate Business Development & Scientific Affairs, Rheonix, Inc.
"I have never heard so many good lectures in so little time. Excellent program! Would go again next year." - Peter Timmerman, Chief Technology Officer, Pepscan Therapeutics
"TIDES 2011 was a very productive conference. I had lots of good meetings, with many types of companies. The marriage of the conferences on discovery and manufacturing will make this event a must be for people interested in the TIDES, particularly the oligonucleoTIDES field." - Sven Klussmann, Ph.D., Chief Scientific Officer, NOXXON Pharma AG, Germany
"The TIDES 2011 Conference was a very well organised event. I enjoyed the conference and found it a very good networking platform with vendors and other attendees from various pharmaceutical companies. I shared my latest data in a poster presentation which sparked off some interesting conversations, and I will be applying my learning's from the conference in my day to day investigations." - Nainesh Patel, Senior Scientist, GlaxoSmithKline, UK
"TIDES is an excellent meeting to catch up on the latest efforts in industry on peptide therapeutics and technologies." - Suresh M. Pitram, Senior Research Investigator, Integrated Diagnostics
"Excellent oligonucleotide chemistry, discovery and optimization…" - Steve Shrewsbury, Chief Medical Officer, AVI Biopharma



